Medicare Insights

The U.S. Food and Drug Administration (FDA) approved Quviviq (daridorexant) 25 mg and 50 mg tablets on January 10, 2022. Manufactured by Idorsia Pharmaceuticals US Inc., this sedative/hypnotic is indicated for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Read more...

On June 6, 2022, the Supreme Court ruled 7-2 in Gallardo v. Marstiller that Florida Medicaid was permitted reimbursement from a settlement involving a permanently disabled woman. The woman, Ms. Gallardo, was involved in a catastrophic injury when she was hit by a truck while exiting a school bus. Florida Medicaid previously paid $862,688.77 in medical expenses and was expected to continue paying for future medical expenses related to this incident. Read more...

The Centers for Medicare and Medicaid Services (CMS) held a webinar on April 13, 2022, to discuss their new initiative, Go Paperless. Go Paperless provides Responsible Reporting Entities (RREs) the ability to receive Medicare correspondence digitally through the Medicare Secondary Payer Recovery Portal (MSPRP). Read more...

On March 28, 2022, a Sixth District Court (Southern District of Ohio Eastern Division) issued an Opinion and Order holding that Medicare Advantage Organizations (MAOs) have a private right of action for double damages under 42 U.S.C. § 1395y(b)(3)(A). Read more...

On Wednesday, April 13, 2022, the Centers for Medicare and Medicaid Services (CMS) will host an overview of the new “Go Paperless” feature available in the Medicare Secondary Payer Recovery Portal (MSPRP). Read more...

Subscribe today to receive our latest blogs, articles, podcasts and more.

	Gastrointestinal medication Zelnorm® (tegaserod) withdrawn from the market July 14, 2022 · Clinical Team Effective June 30, 2022, Zelnorm 6 mg tablet will no longer be produced and marketed in the United States, as announced by its manufacturer, Alfasigma USA, Inc. Read more...
	New insomnia treatment Quviviq™ now on the market July 06, 2022 · Clinical Team The U.S. Food and Drug Administration (FDA) approved Quviviq (daridorexant) 25 mg and 50 mg tablets on January 10, 2022. Manufactured by Idorsia Pharmaceuticals US Inc., this sedative/hypnotic is indicated for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Read more...
	Supreme Court permits Florida Medicaid to seek reimbursement from settlement amounts representing payment of past or future medical care June 24, 2022 · Medicare Insights Team On June 6, 2022, the Supreme Court ruled 7-2 in Gallardo v. Marstiller that Florida Medicaid was permitted reimbursement from a settlement involving a permanently disabled woman. The woman, Ms. Gallardo, was involved in a catastrophic injury when she was hit by a truck while exiting a school bus. Florida Medicaid previously paid $862,688.77 in medical expenses and was expected to continue paying for future medical expenses related to this incident. Read more...
	RREs can opt in for paperless CMS correspondence May 05, 2022 · Medicare Insights Team The Centers for Medicare and Medicaid Services (CMS) held a webinar on April 13, 2022, to discuss their new initiative, Go Paperless. Go Paperless provides Responsible Reporting Entities (RREs) the ability to receive Medicare correspondence digitally through the Medicare Secondary Payer Recovery Portal (MSPRP). Read more...
	States COVID Statutes and their impact on Medicare Set-Asides April 27, 2022 · Medicare Insights Team Read more...
	Sixth Circuit District Court holds Medicare Advantage Organizations have a Private Right of Action Under 42 U.S.C. § 1395y(b)(3)(A) April 13, 2022 · Medicare Insights Team On March 28, 2022, a Sixth District Court (Southern District of Ohio Eastern Division) issued an Opinion and Order holding that Medicare Advantage Organizations (MAOs) have a private right of action for double damages under 42 U.S.C. § 1395y(b)(3)(A). Read more...
	CMS MSPRP “Go Paperless” webinar information April 07, 2022 · Medicare Insights Team On Wednesday, April 13, 2022, the Centers for Medicare and Medicaid Services (CMS) will host an overview of the new “Go Paperless” feature available in the Medicare Secondary Payer Recovery Portal (MSPRP). Read more...
	CMS released updated WCMSA Reference Guide March 29, 2022 · Medicare Insights Team On March 15, the Centers for Medicare and Medicaid Services (CMS) released an updated Workers’ Compensation Medicare Set-Aside Arrangement (WCMSA) Reference Guide (Version 3.6). Read more...

Medicare Insights

Through an integrated medical, pharmacy, claims and legal approach, we deliver insights to help navigate the ever‑changing Medicare Secondary Payer landscape.

Recent blog posts